$2.72
3.03%
Nasdaq, Jul 03, 10:38 pm CET
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

ImmunityBio Inc Stock price

$2.72
+0.01 0.37% 1M
-0.09 3.20% 6M
+0.16 6.25% YTD
-3.56 56.69% 1Y
-1.27 31.83% 3Y
-9.27 77.31% 5Y
-31.92 92.15% 10Y
-31.92 92.15% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
+0.08 3.03%
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

Key metrics

Basic
Market capitalization
$2.4b
Enterprise Value
$3.1b
Net debt
$720.4m
Cash
$61.6m
Shares outstanding
853.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
76.9 | 24.4
EV/Sales
100.0 | 31.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-127.7%
Return on Equity
84.6%
ROCE
-123.1%
ROIC
-137.2%
Debt/Equity
-1.3
Financials (TTM | estimate)
Revenue
$31.2m | $98.5m
EBITDA
$-311.4m | -
EBIT
$-313.4m | $-286.7m
Net Income
$-409.1m | $-410.9m
Free Cash Flow
$-376.9m
Growth (TTM | estimate)
Revenue
10,306.7% | 567.8%
EBITDA
9.4% | -
EBIT
9.4%
Net Income
31.9% | 0.6%
Free Cash Flow
8.7%
Margin (TTM | estimate)
Gross
76.9%
EBITDA
-997.4% | -
EBIT
-1,003.8%
Net
-1,310.3% | -417.2%
Free Cash Flow
-1,207.2%
More
EPS
$-0.5
FCF per Share
$-0.4
Short interest
31.7%
Employees
680
Rev per Employee
$20.0k
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a ImmunityBio Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a ImmunityBio Inc forecast:

Buy
91%
Hold
9%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
10,307% 10,307%
100%
- Direct Costs 0.06 0.06
-
0%
24 24
-
77%
- Selling and Administrative Expenses 160 160
15% 15%
511%
- Research and Development Expense 183 183
10% 10%
586%
-311 -311
9% 9%
-998%
- Depreciation and Amortization 2 2
0% 0%
6%
EBIT (Operating Income) EBIT -313 -313
9% 9%
-1,004%
Net Profit -409 -409
32% 32%
-1,310%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Positive
Seeking Alpha
25 days ago
ImmunityBio, Inc.'s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva's indications could reach $900 million by 2028, implying a 73% upside, but this is far from guaranteed. The company's lymphopenia treatment would face zero competition and would provide a larger addressable market.
Neutral
Business Wire
about one month ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a well-established root cause of early mortality in patients with cancer across all tumor types, correlates with significant improved survival. While an...
Neutral
Business Wire
about one month ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of its Cancer BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), to treat lymphopenia in adult patients with refractory or relapsed solid tumors ...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 680
Founded 2014
Website immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today